Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: A case report

Journal of Medical Case Reports

Volumn 8, Issue 1, 2014, Pages

  Caocci, Giovanni ^a,b   Greco, Marianna ^a   La Nasa, Giorgio ^a,b  

^a Binaghi Hospital   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Chronic myeloid leukemia; Imatinib; Killer immunoglobulin like receptors; Nilotinib; Tyrosine kinase inhibitor discontinuation

Indexed keywords

IMATINIB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER PATIENT; CASE REPORT; CAUCASIAN; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HAPLOTYPE; HUMAN; MALE; MIDDLE AGED; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PYRIMIDINES; WITHHOLDING TREATMENT;

EID: 84907063896     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-8-295     Document Type: Article

References (12)

1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini A, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sauβele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, et al. Blood 2013 122 872 884 10.1182/blood-2013-05-501569 23803709
2. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chroniques, Lancet Oncol 2010 11 1029 1035 10.1016/S1470-2045(10)70233-3 20965785
3. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP, Blood 2013 122 515 522 10.1182/blood-2013-02-483750 23704092
4. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J, Leuk Lymphoma in press doi:10.3109/10428194.2013.831092
5. Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts [abstract]. Rea D, Rousselot P, Guilhot F, Tulliez M, Nicolini FE, Guerci-Bresler A, Legros L, Gardembas M, Giraudier S, Guillerm G, Mahon FX, Blood 2012 120 21 ASH Annual Meeting Abstracts issue bstract 916
6. Discontinuation of dasatinib in patients with CML who have maintained complete molecular response for at least one year: results from a prospective discontinuation (DADI) trial [abstract]. Tanaka H, Imagawa J, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Morita S, Sakamoto J, Kimura S, Am Soc Hematol 2013 122 21 ASH Annual Meeting Abstracts issue bstract 3998
7. Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP, Haematologica 2011 96 1720 1722 10.3324/haematol.2011.048165 21828123
8. Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia. Gadó K, Matolcsy A, Csomor J, Kicsi D, Bödör C, Domján G, Exp Hematol Oncol 2012 1 17 10.1186/2162-3619-1-17 23210842
9. Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors. Aoki J, Ohashi K, Kobayashi T, Kakihana K, Hirashima Y, Sakamaki H, Leuk Lymphoma 2012 53 1412 1414 10.3109/10428194.2011.649753 22168276
10. Current management of CML patients: summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, Vigneri P, Saglio G, Crit Rev Oncol Hematol 2013 12 17
11. Homozygosity for killer immunoglobulin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. La Nasa G, Caocci G, Littera R, Atzeni S, Vacca A, Mulas O, Langiu M, Greco M, Orrù S, Orrù N, Floris A, Carcassi C, Exp Hematol 2013 41 424 431 10.1016/j.exphem.2013.01.008 23380384
12. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K, Haematologica 2012 97 903 906 10.3324/haematol.2011.056853 22180435